Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: NATIONAL COMPREHENSIVE CANCER NETWORK · Firm: TARPLIN, DOWNS & YOUNG, LLC
biomarker testing, cost-sharing elimination on breast/prostate, HR1 implementation, fertility preservation
Combating Organized Retail Crime Act of 2025
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TOLMAR INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FRESENIUS MEDICAL CARE via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Source: Senate LDA
| ALZHEIMER'S ASSOCIATION | 82 | 2009–2026 |
| BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) | 82 | 2006–2026 |
| VERTEX PHARMACEUTICALS INCORPORATED | 82 | 2008–2026 |
| PHRMA | 76 | 2008–2026 |
| SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) | 75 | 2009–2026 |
| NATIONAL ELECTRICAL MANUFACTURERS ASSOCIATION (MITA) | 70 | 2007–2023 |
| ADVAMED | 63 | 2006–2026 |
| BD (BECTON, DICKINSON AND COMPANY) | 63 | 2011–2026 |
| THORN RUN PARTNERS (ON BEHALF OF THE PARTNERSHIP TO IMPROVE PATIENT CARE) | 63 | 2011–2025 |
| ABBVIE, INC. | 58 | 2013–2026 |
| JAZZ PHARMACEUTICALS INC. | 58 | 2012–2025 |
| SAREPTA THERAPEUTICS | 54 | 2014–2026 |
| MERCK | 49 | 2015–2026 |
| TRIPLE-S MANAGEMENT CORPORATION | 45 | 2016–2026 |
| ELI LILLY AND COMPANY | 43 | 2017–2026 |
| ABBOTT (FORMERLY KNOWN AS ALERE INC.) | 42 | 2017–2026 |
| AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) | 42 | 2017–2026 |
| MALLINCKRODT PHARMACEUTICALS | 41 | 2013–2022 |
| GAINWELL TECHNOLOGIES (FKA HEALTH MANAGEMENT SYSTEMS) | 40 | 2017–2026 |
| HEALTH CARE SERVICE CORPORATION | 40 | 2017–2026 |
| AMERICAN OSTEOPATHIC ASSOCIATION | 38 | 2018–2026 |
| GENENTECH INC | 38 | 2018–2026 |
| LINCARE | 38 | 2018–2026 |
| PFIZER | 37 | 2012–2020 |
| GILEAD SCIENCES, INC. | 34 | 2019–2026 |
| CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) | 29 | 2020–2026 |
| FOUNDATION MEDICINE | 29 | 2020–2026 |
| NOVO NORDISK, INC. | 29 | 2020–2026 |
| AMERICAN HOMEPATIENT | 28 | 2006–2014 |
| BOEHRINGER INGELHEIM | 28 | 2020–2026 |
| GENTIVA (FORMERLY REPORTED AS HUMANA & KINDRED AT HOME) | 28 | 2020–2025 |
| LONGEVITY HEALTH PLAN | 28 | 2020–2026 |
| THE AMPUTEE COALITION | 28 | 2020–2026 |
| NEUROCRINE BIOSCIENCES, INC | 25 | 2021–2026 |
| BRISTOL MYERS SQUIBB | 24 | 2021–2026 |
| BAXTER | 23 | 2017–2022 |
| NOVOCURE INC. | 23 | 2021–2026 |
| TAKEDA PHARMACEUTICALS AMERICA INC | 23 | 2017–2022 |
| ACCENTURE FEDERAL SERVICES | 22 | 2021–2026 |
| AMYLYX PHARMACEUTICALS | 20 | 2022–2026 |
| FLAGSHIP PIONEERING | 20 | 2022–2026 |
| SAS | 20 | 2022–2026 |
| BOSTON SCIENTIFIC CORPORATION | 18 | 2008–2012 |
| 10X GENOMICS | 17 | 2020–2023 |
| 3M | 17 | 2012–2016 |
| ONE MEDICAL | 17 | 2020–2023 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 17 | 2019–2022 |
| AIS HEALTHCARE | 16 | 2021–2024 |
| H2 HEALTH | 16 | 2020–2026 |
| NOVARTIS | 16 | 2023–2026 |
| QUEST DIAGNOSTICS | 16 | 2023–2026 |
| SIGNIFY (F.K.A. REMEDY BPCI PARTNERS, LLC) | 15 | 2019–2022 |
| VALNEVA USA, INC | 15 | 2023–2026 |
| DENDREON CORPORATION | 14 | 2011–2013 |
| EXCELLUS HEALTH PLAN INC. | 14 | 2023–2026 |
| CALIFORNIA PROTONS CANCER THERAPY CENTER | 13 | 2019–2022 |
| COUNCIL FOR MEDICARE INTEGRITY (AMER COALITION FOR HEALTHCARE CLAIMS INTEGRITY) | 13 | 2014–2017 |
| AMNEAL PHARMACEUTICALS, INC. | 12 | 2024–2026 |
| ASTELLAS PHARMA US, INC. | 12 | 2024–2026 |
| MEDICAL FACULTY ASSOCIATES, INC. | 12 | 2021–2022 |
| OPTION CARE HEALTH | 12 | 2023–2025 |
| HEALTHCARE LEADERSHIP COUNCIL | 11 | 2021–2023 |
| IDORSIA PHARMACEUTICALS US INC | 11 | 2023–2025 |
| MEDICALLY HOME | 11 | 2022–2024 |
| NATIONAL SEATING & MOBILITY | 11 | 2024–2026 |
| WYETH | 11 | 2006–2009 |
| HANSA BIOPHARMA | 10 | 2024–2026 |
| AMAZON.COM SERVICES LLC | 9 | 2024–2025 |
| AIMMUNE THERAPEUTICS | 8 | 2019–2020 |
| NATIONAL HOME INFUSION ASSOCIATION | 8 | 2015–2017 |
| PHREESIA | 8 | 2025–2026 |
| PRIORITY ON DEMAND | 8 | 2025–2026 |
| AVAILITY | 7 | 2024–2025 |
| LOCAL HEALTH PLANS OF CALIFORNIA | 7 | 2025–2026 |
| REPLIMUNE INC. | 7 | 2025–2026 |
| SANOFI-AVENTIS | 7 | 2006–2008 |
| BLUEPRINT BIOSECURITY ACTION | 6 | 2025–2026 |
| KIDNEY CARE COUNCIL | 6 | 2006–2008 |
| NORWEGIAN CRUISE LINE HOLDINGS | 6 | 2020–2021 |
| OCTAVIANT FINANCIAL INC. | 6 | 2023–2024 |
| OPEN PHILANTHROPY ACTION FUND | 6 | 2021–2022 |
| TERSERA THERAPEUTICS | 6 | 2025–2026 |
| WHOOP | 6 | 2025–2026 |
| ADVOCATES FOR COMMUNITY HEALTH | 5 | 2023 |
| EVERGREEN NEPHROLOGY | 5 | 2024 |
| HEALTH GORILLA | 5 | 2023 |
| Hims & Hers Health, Inc. | 5 | 2023–2024 |
| NATIONAL COMPREHENSIVE CANCER NETWORK | 5 | 2025–2026 |
| AMERICAN INVESTMENT COUNCIL | 4 | 2023 |
| CARDEN & ASSOCIATES | 4 | 2007 |
| UNITED NETWORK FOR ORGAN SHARING | 4 | 2025 |
| AMERICAN ACADEMY OF PEDIATRICS | 3 | 2024 |
| BIOGEN IDEC | 3 | 2006–2007 |
| NATIONAL COALITION FOR ASSISTIVE AND REHAB TECHNOLOGY | 3 | 2009 |
Combating Organized Retail Crime Act of 2025
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act Education around issues facing pharmacies, including Main Street Pharmacy Access Act (H.R. 3164)
Ensuring Community Access to Pharmacist Services Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act Education around issues facing pharmacies, including Main Street Pharmacy Access Act (H.R. 3164)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program for Indians Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
ISLET Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
ISLET Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Military Next-Gen Collision Avoidance Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Military Next-Gen Collision Avoidance Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Health Care Cybersecurity and Resiliency Act of 2026
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule Education around issues facing independent physicians, including S. 3822, the Break Up Big Medicine Act S.3315 and House draft, Healthcare Cybersecurity and Resiliency Act
Break Up Big Medicine Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule Education around issues facing independent physicians, including S. 3822, the Break Up Big Medicine Act S.3315 and House draft, Healthcare Cybersecurity and Resiliency Act
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
SCREEN for Type 1 Diabetes Act of 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: NATIONAL COMPREHENSIVE CANCER NETWORK · Firm: TARPLIN, DOWNS & YOUNG, LLC
biomarker testing, cost-sharing elimination on breast/prostate, HR1 implementation, fertility preservation
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: NATIONAL COMPREHENSIVE CANCER NETWORK · Firm: TARPLIN, DOWNS & YOUNG, LLC
biomarker testing, cost-sharing elimination on breast/prostate, HR1 implementation, fertility preservation, Medicare/commercial payment and coverage of cancer services
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: NATIONAL COMPREHENSIVE CANCER NETWORK · Firm: TARPLIN, DOWNS & YOUNG, LLC
biomarker testing, cost-sharing elimination on breast/prostate, HR1 implementation, fertility preservation, Medicare/commercial payment and coverage of cancer services
Full-Year Continuing Appropriations and Extensions Act, 2025
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S 891 Bipartisan Healthcare Act; HR 1968 Full Year Continuing Appropriations and Extensions Act of 2025, PL 119-4.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program for Indians Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program for Indians Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
Drug safety, prescription drug abuse, value of prescription drugs; HR 946/S 1862 Orphan Cures Act; Health care issues H.R. 1 (Public Law No: 119-21)
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Special Diabetes Program Reauthorization Act of 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 2211 - A bill to reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians H.R. 5461 - the Special Diabetes Program Reauthorization Act of 2025 H.R. 5488 - To amend title III of the Public Health Service Act to extend funding for the Special Diabetes Program for Indians Issues pertaining to NIH research Issues pertaining to cell and gene therapies Issues pertaining to c-peptide Issues pertaining to the United States Preventive Services Taskforce
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4121 / S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304 / S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5371 Continuing Appropriations and Extensions Act of 2026
Bipartisan Health Care Act
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to the expiration/extension of Priority Review Vouchers (PRVs) for rare disease; S 891 Bipartisan Healthcare Act; HR 1968 Full Year Continuing Appropriations and Extensions Act of 2025, PL 119-4.
American Relief Act, 2025
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 8467 - Farm, Food, and National Security Act of 2024 H.R. 10545 - American Relief Act of 2025 Drug safety, prescription drug abuse, value of prescription drugs
American Relief Act, 2025
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 3435 - the Charitable Act S. 566 - the Charitable Act H.R. 10545 American Relief Act of 2025 H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes
PSA Screening for HIM Act
Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing
PSA Screening for HIM Act
Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing
PSA Screening for HIM Act
Client: ASTELLAS PHARMA US, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
The PSA Screening for HIM Act (H.R. 1826/S. 2821) menopause, drug pricing
Special Diabetes Program Reauthorization Act of 2023
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act (AKAC) S. 3234, Chronic Disease Flexible Coverage Act
Making further continuing appropriations for the fiscal year ending September 30, 2024, and for other purposes.
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25
Making further continuing appropriations for the fiscal year ending September 30, 2024, and for other purposes.
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25
Making further continuing appropriations for the fiscal year ending September 30, 2024, and for other purposes.
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Issues pertaining to NIH appropriations for FY25
Further Consolidated Appropriations Act, 2024
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4336, the Consolidated Appropriations Act, 2024 (P.L. 118-42) H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47) Drug safety, prescription drug abuse, value of prescription drugs, expiring healthcare extenders
Charitable Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 3435 - the Charitable Act S. 566 - the Charitable Act H.R. 10545 American Relief Act of 2025 H.R.5894 - Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes
American Broadband Deployment Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
American Broadband Deployment Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
American Broadband Deployment Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
American Broadband Deployment Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
State Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
State Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
State Strategic Stockpile Act of 2023
Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization
State Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
State Strategic Stockpile Act of 2023
Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization
State Strategic Stockpile Act of 2023
Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization
State Strategic Stockpile Act of 2023
Client: VALNEVA USA, INC · Firm: TARPLIN, DOWNS & YOUNG, LLC
S.2080 Strengthening America's Strategic National Stockpile Act H.R.3631 State Strategic Stockpile Act vaccine access, pandemic preparedness, PAHPA reauthorization
State Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Improving Public Health Preparedness Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Improving Public Health Preparedness Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Improving Public Health Preparedness Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Improving Public Health Preparedness Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
SCREENS for Cancer Act of 2024
Client: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.3916/S.1840 - SCREENS for Cancer Act of 2023 IRA implementation, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED
SCREENS for Cancer Act of 2024
Client: AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.3916/S.1840 - SCREENS for Cancer Act of 2023 IRA implementation, childhood cancer, access and coverage, prescription drug pricing and access, health disparities, cancer screenings, prostate cancer screenings, PCHETA, MCED
Essential Medicines Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Essential Medicines Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Essential Medicines Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Essential Medicines Strategic Stockpile Act of 2023
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Preserving Patient Access to Home Infusion Act
Client: OPTION CARE HEALTH · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.4104/S.1976 - Preserving Patient Access to Home Infusion Act Medicare coverage and payment for home infusion services
Preserving Patient Access to Home Infusion Act
Client: OPTION CARE HEALTH · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.4104/S.1976 - Preserving Patient Access to Home Infusion Act Medicare coverage and payment for home infusion services
Summer Meals REACH Act of 2023
Client: JAZZ PHARMACEUTICALS INC. · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 4336, the Consolidated Appropriations Act, 2024 (P.L. 118-42) H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47) Drug safety, prescription drug abuse, value of prescription drugs, expiring healthcare extenders
Consolidated Appropriations Act, 2024
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25
Consolidated Appropriations Act, 2024
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act Issues pertaining to NIH appropriations for FY25
Consolidated Appropriations Act, 2024
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024 H.R. 4366 - Consolidated Appropriations Act of 2024 H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act S. 4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Issues pertaining to NIH appropriations for FY25
Preparing for All Hazards and Pathogens Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Preparing for All Hazards and Pathogens Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Preparing for All Hazards and Pathogens Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Preparing for All Hazards and Pathogens Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Small Business Tax Fairness and Compliance Simplification Act
Client: THORN RUN PARTNERS (ON BEHALF OF THE PARTNERSHIP TO IMPROVE PATIENT CARE) · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.45 - Small Business Tax Fairness and Compliance Simplification Act IRA implementation, patient engagement, alternative payment models
Support for Patients and Communities Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Support for Patients and Communities Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Support for Patients and Communities Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act HR 6992/S. 2364 - MAPS Act H.R.9540 - Fight Illicit Pill Presses Act of 2024 H.R. 8261, the Preserving Telehealth, Hospital, and Ambulance Access Act H.R. 7623, Telehealth Modernization Act of 2024 General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Support for Patients and Communities Reauthorization Act
Client: HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) · Firm: TARPLIN, DOWNS & YOUNG, LLC
HR 405 Essential Medicines Strategic Stockpile Act of 2023 HR 3837 Improving Public Health Preparedness Act HR 3557: Medical and Health Stockpile Accountability Act HR 3631/S 2080: State Strategic Stockpile Act HR 4421: Reauthorization of the Pandemic All-Hazards Preparedness Act H.R.4531/S. 2433 - Support for Patients and Communities Reauthorization Act S.2510 - RAPID Reserve Act General Issues Related to Drug Shortages including Senate Finance Proposal and Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile
Accelerating Kids’ Access to Care Act
Client: BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) · Firm: TARPLIN, DOWNS & YOUNG, LLC
S. 4504/H.R. 8698 - SCREEN for Type 1 Diabetes Act S. 1855/H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023 S. 1269 - INSULIN Act of 2023 H.R. 4758/S.2372, Accelerating Kids Access to Care Act (AKAC) S. 3234, Chronic Disease Flexible Coverage Act
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY AND COMPANY · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.4818 - Treat and Reduce Obesity Act of 2023 Medicare & Medicaid payments and coverage issues, Medicare Part D, Medicare Part B, 340B
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY AND COMPANY · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.4818 - Treat and Reduce Obesity Act of 2023 Medicare & Medicaid payments and coverage issues, Medicare Part D, Medicare Part B, 340B
Treat and Reduce Obesity Act of 2023
Client: ELI LILLY AND COMPANY · Firm: TARPLIN, DOWNS & YOUNG, LLC
H.R.4818 - Treat and Reduce Obesity Act of 2023 Medicare & Medicaid payments and coverage issues, Medicare Part D, Medicare Part B, 340B
lobbying related to medicare policy, ESRD
Filing targets: Centers For Medicare and Medicaid Services (CMS)
TOLMAR INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · RR
Medicare policy
FRESENIUS MEDICAL CARE via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · RR
lobbying related to medicare policy, ESRD
WHOOP via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Health tech, removal of barrier / maintain existing flexibility to allow access to health tech wellness products
lobbying related to Medicare coverage and health technology
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical and Medicare/Medicaid policy
Lobbying related to pharmaceutical policy
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRIPLE-S MANAGEMENT CORPORATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to Medicare and Medicaid policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TERSERA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare payment policy
Filing targets: Centers For Medicare and Medicaid Services (CMS)
SAS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care technology and program integrity.
Lobbying related to health care technology and program integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
SAREPTA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to rare disease policy and coverage
Lobbying related to rare disease policy
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
federal budget issues
Lobbying related to pharmaceutical policy and Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REPLIMUNE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · 3A
innovation in rare cancer treatment
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
REPLIMUNE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
innovation in rare cancer treatment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QUEST DIAGNOSTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to diagnostics and Medicare reimbursement policy.
Lobbying related to diagnostics and Medicare reimbursement policy.
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PRIORITY ON DEMAND via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicaid and Medicare and health care coverage policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PHRMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical and Medicare & Medicaid policy
Lobbying related to pharmaceutical policy
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHREESIA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
patient engagement, health care technology
Medicare innovation, patient engagement
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVOCURE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to regulatory policy
Lobbying related to Medicare coverage and reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVO NORDISK INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy and access
Federal budget issues
Lobbying related to pharmaceutical policy and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to trade
Lobbying related to pharmaceutical policy
Federal budget issues
Lobbying related to pharmaceutical policy
NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
telehealth, mental health, prescription drug pricing, payment reform
federal budget issues
IRA, prescription drug pricing, payment reform, innovation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL SEATING & MOBILITY via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare coverage and reimbursement policy
Lobbying related to Medicare coverage and reimbursement policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL COMPREHENSIVE CANCER NETWORK via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care coverage and patient access policy.
Lobbying related to health care coverage and patient access policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MERCK via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Federal budget issues
IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA
IRA, Medicare and Medicaid payment and coverage issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LONGEVITY HEALTH PLAN via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare Advantage and managed care policy
Lobbying related to Medicare Advantage and managed care policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LOCAL HEALTH PLANS OF CALIFORNIA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicaid and health care coverage policy
Lobbying related to Medicaid and health care coverage policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LINCARE via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to Medicare coverage and reimbursement policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act Education around issues facing pharmacies, including Main Street Pharmacy Access Act (H.R. 3164)
General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule Education around issues facing independent physicians, including S. 3822, the Break Up Big Medicine Act S.3315 and House draft, Healthcare Cybersecurity and Resiliency Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
HEALTH CARE SERVICE CORPORATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Issues related to tax advantage savings vehicles for health expenses
Lobbying related to health care access and coverage policy
Lobbying related to health care access and coverage policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HANSA BIOPHARMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · 3T
Federal budget issues
Kidney issues, access to innovation, rare disease issues, organ rejection
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H2 HEALTH via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Medicare and Medicaid reimbursement and coverage of therapy services
Medicare and Medicaid reimbursement and coverage of therapy services
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare & Medicaid and pharmaceutical policy
Federal budget issues
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
FOUNDATION MEDICINE via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to diagnostics and health care policy.
Lobbying related to diagnostics and health care policy and payment issues
supply chain
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
ELI LILLY AND COMPANY via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
federal budget issues
Medicare & Medicaid payment and coverage issues, lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EXCELLUS HEALTH PLAN, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Medicare Advantage, Medicare reimbursement and payment issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ELEVANCE HEALTH, INC (F.K.A. ANTHEM, INC. & WELLPOINT, INC.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Federal budget issues
Lobbying related to health care access, Medicare, and Medicaid policy
Lobbying related to health care access
CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical supply
Federal budget issues
lobbying related to Medicare and Medicaid
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL MYERS SQUIBB via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy
Medicare & Medicaid payment and coverage issues
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BOEHRINGER INGELHEIM via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to Medicare & Medicaid coverage and payment issues
federal budget issues
Lobbying related to pharmaceutical policy
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
S. 4612/H.R. 9000 - the SCREEN For T1D Act S. 8270/H.R. 8018 - the ISLET Act Issues pertaining to cell and gene therapies Issues pertaining to C-peptide Issues pertaining to NIH research Issues pertaining to Special Diabetes Program Issues pertaining to FDA modernization
H.R. 8646, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H.R. 9620, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 Issues pertaining to NIH & FDA funding
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BLUE CROSS BLUE SHIELD ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
issues related to tax
Lobbying related to Medicare and Medicaid policy
BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical and health care policy and Medicare & Medicaid payment and coverage issues
Federal budget issues
Lobbying related to pharmaceutical, tax, and health care policy
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Medicare & Medicaid coverage and reimbursement issues
Lobbying related to health care policy and research funding
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care policy and research funding
federal budget issues
Medicare & Medicaid coverage and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTELLAS PHARMA US, INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMYLYX PHARMACEUTICALS via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
rare disease and access to innovation
rare disease and access to innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMNEAL PHARMACEUTICALS, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
federal budget issues
Lobbying related to domestic pharmaceutical supply
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy and Medicare policy
federal budget issues
Lobbying related to pharmaceutical policy and health care access
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
AMERICAN OSTEOPATHIC ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to physician payment and workforce
federal budget issues
Lobbying related to physician payment and workforce
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to pharmaceutical policy and Medicare and Medicaid policy
federal budget issues
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN CANCER SOCIETY CANCER ACTION NETWORK (ACSCAN) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to health care policy, access, and coverage
federal budget issues
Lobbying related to health care policy, access and coverage, and Medicare & Medicaid policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVAMED via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
Lobbying related to medical device policy and Medicare reimbursement/coverage.
Lobbying related to medical device policy, innovation, technology policy, right to repair and Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ABBOTT (FORMERLY KNOWN AS ALERE INC.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
issues related to national trade
Lobbying related to health care policy, Medicare reimbursement
Lobbying related to health care policy, Medicare reimbursement
ABBVIE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · third_quarter · Q3
drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA
Part B, Part D, drug pricing and access, negotiation,
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BREAKTHROUGH T1D (FKA JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to disease research, and innovation
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOTECHNOLOGY INDUSTRY ORGANIZATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical and health care policy
Lobbying related to pharmaceutical and health care policy and Medicare & Medicaid payment and coverage issues
Federal budget issues
HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
General Issues Related to Drug Shortages including Drug Shortages Appropriations Requests General Issues Related to the Strategic National Stockpile General Issues Related to Pharmaceutical Supply Chain General Issues Related to Proposed Physician Fee Schedule Rule General Issues Related to Supply Chain Ownership
General Issues Related to report language regarding paper inserts H.R. 2853, Combating Organized Retail Crime Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
ABBVIE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Part B, Part D, drug pricing and access, negotiation,
federal budget issues
drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
MERCK via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
IRA, Medicare and Medicaid payment and coverage issues
Federal budget issues
IRA, innovation, drug pricing in federal programs, hepatitis C, HPV, transparency, drug pricing, vaccines, biosimilars, PAHPA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVARTIS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Federal budget issues
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
SAS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care technology and program integrity.
Lobbying related to health care technology and program integrity.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office
TERSERA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare payment policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TRIPLE-S MANAGEMENT CORPORATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare and Medicaid policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H2 HEALTH via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Medicare reimbursement and coverage of therapy services
Medicare reimbursement and coverage of therapy services
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
FLAGSHIP PIONEERING via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Preemptive/preventive health, pandemic preparedness, life science innovation and competitiveness, biomanufacturing, AI policy and regulation, rare disease policy and regulation, platform technology policy and regulation, broad based investment in US biotech
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
REPLIMUNE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
innovation in rare cancer treatment
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALZHEIMER'S ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care policy and research funding
federal budget issues
Medicare & Medicaid coverage and reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN OSTEOPATHIC ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to physician payment and workforce
Lobbying related to physician payment and workforce
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BLUE CROSS BLUE SHIELD ASSOCIATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
issues related to tax
federal budget issues
Lobbying related to coverage, health insurance policy, and Medicare & Medicaid policy
HEALTH CARE SERVICE CORPORATION via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care access and coverage policy
Lobbying related to health care access and coverage policy
Issues related to tax advantage savings vehicles for health expenses
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL MYERS SQUIBB via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
federal budget issues
Medicare & Medicaid payment and coverage issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ELEVANCE HEALTH, INC (F.K.A. ANTHEM, INC. & WELLPOINT, INC.) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to health care access, Medicare, and Medicaid policy
Lobbying related to health care access
Tax policy
LOCAL HEALTH PLANS OF CALIFORNIA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicaid and health care coverage policy
Lobbying related to Medicaid and health care coverage policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHRMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · 2A
Lobbying related to pharmaceutical and Medicare & Medicaid policy
Federal budget issues
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHRMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical and Medicare & Medicaid policy
Federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRIORITY ON DEMAND via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicaid and health care coverage policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
EXCELLUS HEALTH PLAN, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Medicare Advantage, Medicare reimbursement and payment issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NOVO NORDISK INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Federal budget issues
Lobbying related to pharmaceutical policy and access
Lobbying related to pharmaceutical policy and access
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
WHOOP via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Health tech, removal of barrier / maintain existing flexibility to allow access to health tech wellness products
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SAREPTA THERAPEUTICS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to rare disease policy
Lobbying related to rare disease policy and coverage
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC (FORMERLY KNOWN AS GENZYME CORPORATION) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
federal budget issues
Lobbying related to pharmaceutical policy and Medicare coverage
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PHREESIA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Federal budget issues
Medicare innovation, patient engagement
patient engagement, health care technology
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL SEATING & MOBILITY via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare coverage and reimbursement policy
Lobbying related to Medicare coverage and reimbursement policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NOVOCURE INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare coverage and reimbursement
Lobbying related to regulatory policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NEUROCRINE BIOSCIENCES, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
telehealth, mental health, prescription drug pricing, payment reform
IRA, prescription drug pricing, payment reform, innovation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LONGEVITY HEALTH PLAN via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare Advantage and managed care policy
Lobbying related to Medicare Advantage and managed care policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LINCARE via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to Medicare coverage and reimbursement policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HANSA BIOPHARMA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Kidney issues, access to innovation, rare disease issues, organ rejection
Federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GENENTECH, INC. via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Federal budget issues
Lobbying related to Medicare & Medicaid and pharmaceutical policy
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ELI LILLY AND COMPANY via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Medicare & Medicaid payment and coverage issues, lobbying related to pharmaceutical policy
Lobbying related to pharmaceutical policy
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CARDINAL HEALTH (F.K.A. THE GLOVER PARK GROUP) via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical supply
Federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BOEHRINGER INGELHEIM via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
Lobbying related to pharmaceutical policy
Lobbying related to Medicare & Medicaid coverage and payment issues
federal budget issues
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
federal budget issues
Lobbying related to pharmaceutical policy and Medicare and Medicaid policy
Lobbying related to pharmaceutical policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMYLYX PHARMACEUTICALS via TARPLIN, DOWNS & YOUNG, LLC
2026 · second_quarter · Q2
rare disease and access to innovation
rare disease and access to innovation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Lobbying related to health care access, Medicare, and Medicaid policy
Tax policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Lobbying related to coverage, health insurance policy, and Medicare & Medicaid policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
lobbying related to trade issues
Lobbying related to pharmaceutical and health care policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
federal budget issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Lobbying related to pharmaceutical, tax, and health care policy
lobbying related to trade issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Lobbying related to trade
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Lobbying related to Medicare and Medicaid policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Federal budget issues
Lobbying related to health care access, Medicare, and Medicaid policy
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE